MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age7+
SponsorMyositis International Health & Research Collaborative Alliance Foundation

About this trial

Myositis diseases are each rare diseases. As in other rare diseases, people living with myositis diseases face physical and psychosocial challenges that may not be recognized in current research priorities. The PRISMS study is a global investigation that collects patient perspectives through (mostly online) methods of open-ended questions, community forums and survey to identify the most pressing research concerns as identified by patients. Findings will be analyzed to create a patient-voiced set of research priorities that can guide the direction of research and help inform funding decisions across myositis diseases.

Potential participants can express interest via https://mihrafoundation.org/mihra-programs/mihra-patient-contact-registry/

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ability to provide informed consent

Have a clinician diagnosis of an idiopathic inflammatory myopathy or be a care partner or parent of a person living with an idiopathic inflammatory myopathy.

Participants who may have signed up through the MIHRA Patient Contact Registry https://mihrafoundation.org/mihra-programs/mihra-patient-contact-registry/

Disqualifiers

Under the age of 7 years old

Do not have a diagnosis of an inflammatory myopathy

Trial population

Adults and children living with an idiopathic inflammatory myopathy recruited through self-referral (prompted by clinic notices/ patient organization newsletters / /advocacy communities / social media / internet searches ) to provide perspectives on research priorities.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • No intervention - qualitative and mixed methods investigations

    Other intervention

    No Intervention

Treatment groups

700 Participants
are divided into 1 treatment group
Group A: Individuals living with a myositis disease1 intervention

Trial outcomes

Primary outcomes

1

Patient-voiced research priority topics

Number and distribution of coded priority domains identified from data collection that has been stratified by disease type, through thematic analysis (codebook refined iteratively) with subsequent assigned degree of importance and ranked priority.

Time frame
At completion of narrative, focus group forum or survey, up to 90 minute

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Myositis International Health & Research Collaborative Alliance Foundation

Lead sponsor

MIHRA Patient Advisory

Collaborator

Myositis Australia

Collaborator

CureJM

Collaborator

The Myositis Association

Collaborator

The Dutch Myositis Association

Collaborator

The Swedish Myositis Association

Collaborator

Myositis UK

Collaborator

The German Myositis Association

Collaborator

CARRA - Childhood Arthritis & Rheumatology Research Alliance

Collaborator

PReS - Paediatric Rheumatology European Society

Collaborator